Singapore-based health technology startup Mesh Bio and UK-based drug discovery company Multiomic Health have begun collaborating to create a huge multi-Omix dataset that will provide insights into metabolic syndrome-related conditions among Asians.
What is it about
According to a press release, Mesh Bio will tap into the network of healthcare providers to recruit participants for their study, especially patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.
On its part, Multiomic Anonymous will generate genomic, proteomic, metabolic and other omix data from body fluid samples. These omics data will be combined with anonymous data from clinical and diagnostic tests to create a rich multi-omics dataset and to achieve AI-based computational biology models.
The companies will conduct joint projects with other biopharmaceutical and medical technology companies to increase patient stratification for R&D programs at the clinical level.
Why it matters
The large multi-omix datasets they are creating will enable companies to advance their respective R&D programs to develop precise therapeutic and diagnostic products for patients with metabolic syndrome-related conditions.
“Longitudinal multi-omix data combined with in-depth clinical phenotyping are essential for the development of transformative therapeutics and diagnostics in chronic multi-factorial disease,” said Angeli Moller, co-founder of Global Advocacy Group Alliance.
Moller added that the study would help create “specific new and much-needed insights for the Asian population” that have been presented in historical studies of metabolic diseases.
Prior to the epidemic, metabolic diseases, including type 2 diabetes mellitus and chronic kidney disease, accounted for half of the world’s deaths, and multiomic estimates put global healthcare spending at about $ 2 trillion.
During an epidemic, patients with metabolic syndrome constitute a “significant” portion of COVID-19-related hospitalization and death, according to a study published in the medical journal Diabetes Care. Recent studies have further indicated that COVID-19 survivors have an increased risk of developing type 2 diabetes and chronic kidney disease.
Singapore-based intestinal microbiome company AMILI is another organization that aims to fill the gap in intestinal health research representing the Asian population. The company is building a large, multi-ethnic collection of microbiome data and samples from Asia that will help academic institutions and biotech organizations identify new biomarkers for making intestinal health products. Earlier this month, AMILI raised $ 10.5 million in Series A funds that will support its further expansion across Asia.
In other news, metabolic health-centric fitness apps HealthifyMe has recently come up with a new offer that combines health tracking and smart diagnostics. HealthifyPro is a fitness plan that comes with a biosensor system that includes an uninterrupted glucose monitor; An attached smart scale metabolic panel; And support from in-house fitness coach and AI assistant, Rhea.